June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Optical Coherence Tomography Guided Selective Retina Therapy: First results from the CENTAURUS study
Chantal Dysli; Christian Burri; Simon Salzmann; Boris Povazay; Christoph Meier; Martin Frenz; Martin Sebastian Zinkernagel; Sebastian Wolf
Author Affiliations & Notes
  • Chantal Dysli
    Ophthalmology, Inselspital Universitatsspital Bern, Bern, Bern, Switzerland
  • Christian Burri
    optoLab, Institute for Human Centered Engineering, Bern University of Applied Sciences, Biel, Switzerland
    Biomedical Photonics Group, Institute of Applied Physics, University of Bern, Bern, Switzerland
  • Simon Salzmann
    optoLab, Institute for Human Centered Engineering, Bern University of Applied Sciences, Biel, Switzerland
  • Boris Povazay
    optoLab, Institute for Human Centered Engineering, Bern University of Applied Sciences, Biel, Switzerland
  • Christoph Meier
    optoLab, Institute for Human Centered Engineering, Bern University of Applied Sciences, Biel, Switzerland
  • Martin Frenz
    Biomedical Photonics Group, Institute of Applied Physics, University of Bern, Bern, Switzerland
  • Martin Sebastian Zinkernagel
    Ophthalmology, Inselspital Universitatsspital Bern, Bern, Bern, Switzerland
  • Sebastian Wolf
    Ophthalmology, Inselspital Universitatsspital Bern, Bern, Bern, Switzerland
  • Footnotes
    Commercial Relationships   Chantal Dysli None; Christian Burri Heidelberg Engineering, Meridian Medical, Code F (Financial Support), Heidelberg Engineering, Meridian Medical, Code R (Recipient); Simon Salzmann Heidelberg Engineering, Meridian Medical, Code R (Recipient); Boris Povazay None; Christoph Meier None; Martin Frenz None; Martin Zinkernagel Bayer, Boehringer Ingelheim, Novartis, Roche, Zeiss, Code C (Consultant/Contractor), Bayer, Code F (Financial Support); Sebastian Wolf Bayer, Boehringer Ingelheim, EarlySight, Novartis, Roche, Zeiss, Code C (Consultant/Contractor), Bayer, Novartis, Roche, Code F (Financial Support)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1804. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Optical Coherence Tomography Guided Selective Retina Therapy: First results from the CENTAURUS study
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Chantal Dysli, Christian Burri, Simon Salzmann, Boris Povazay, Christoph Meier, Martin Frenz, Martin Sebastian Zinkernagel, Sebastian Wolf; Optical Coherence Tomography Guided Selective Retina Therapy: First results from the CENTAURUS study. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1804.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose : To assess the effect and safety of the SPECTRALIS CENTAURUS device for optical coherence tomography (OCT) guided selective retina therapy (SRT).

Methods : A laser test pattern (2×10 spots, single laser pulses) for damage threshold determination as well as a specified laser treatment pattern for dosimetry simulation (25 spots, ramped up pulse sequence, maximal 30 pulses, 100 Hz repetition rate) are applied in patients with diabetic retinopathy using the SPECTRALIS CENTAURUS device (HuCE-optoLab, BFH-TI, CH). This device consists of an upgraded diagnostic imaging platform (SPECTRALIS HRA+OCT, Heidelberg Engineering, DE) extended with a prototype laser (Meridian Medical; wavelength: 532 nm; peak power: 30 W) for selective retina therapy (SRT). Visual acuity and multimodal imaging using OCT, fluorescein angiography and color fundus photography were assessed in a follow up of six months in order to investigate safety and treatment effects.

Results : Three patients have been included and treated. In all patients, dose dependent laser lesions were induced. No adverse events caused by the treatment, and no device deficiencies have been observed. One week after treatment, OCT-B scans began to show variable thickening of the RPE layer, indicating RPE proliferation. At the latest six months after treatment, the corresponding areas had returned to normal. Neurosensory retinal layers, including the outer photoreceptor layers appeared mostly unaffected in all SRT lesions after six months.

Conclusions : OCT guided selective retina therapy using the SPECTRALIS CENTAURUS device is feasible in patients with diabetic retinopathy without adverse events. After successful completion of the first phase of the study, a second phase is planned to evaluate the biological and structural effects on the retina induced by SRT, especially on intermediate AMD and confluent soft drusen.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Attribution-NonCommercial-NoDerivatives
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept